GRIA2: Glutamate receptor 2
Ionotropic glutamate receptor that functions as a ligand- gated cation channel, gated by L-glutamate and glutamatergic agonists such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), quisqualic acid, and kainic acid.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on GRIA2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Talampanel | Phase 2 | Teva Pharmaceutical Industries | Small molecule | AntagonistGlutamate receptor ionotropic, AMPA 2 antagonist | 0 |
- Neurodevelopmental disorder with language impairment and behavioral abnormalities0.83
- Epilepsy0.61
- Migraine disorder0.59
- Seizure0.57
- Alcohol dependence0.56
- Lennox-Gastaut syndrome0.54
- Focal epilepsy0.45
- Diabetic neuropathy0.44
- Obesity disorder0.43
- Focal-onset seizure0.39
- Parkinson disease0.38
- Hereditary disease0.38
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4016, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P42262, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets